

Inhibitory Effect of *Panax notoginseng* and Berberine on LPS-induced iNOS, COX-2 and Prostaglandin E2

Boo Young Lee, Jin Young Moon¹, Cherl Ho Kim², Won Hwan Park*

Cardiovascular Medical Research Center and Department of Diagnostics, 1: Department of AM-Pointology, 2: Department Biochemistry, College of Korean Medicine, Dongguk University

Many traditional herbal remedies exhibit several beneficial effects including anti-inflammation. *Panax notoginseng* Buck F.H. Chen. is used as a therapeutic agent to stop haemorrhages and a tonic to promote health in Korean and Chinese medicine. The pharmacokinetic profiles of the main *P. notoginseng* are still not accurately investigated. The exact mechanism of the anti-inflammatory action of *P. notoginseng*, however, has not been determined. In the present study, we examined the effect of *P. notoginseng* on lipopolysaccharide (LPS)-induced nitric oxide (NO) production, and inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) gene expression in RAW264.7 macrophages. The results indicated that *P. notoginseng* concentration-dependently inhibited LPS-induced NO production. Furthermore, *P. notoginseng* inhibited the expression of LPS-induced iNOS and COX-2 proteins without an appreciable cytotoxic effect on RAW264.7 cells. Berberine also inhibited LPS-induced iNOS protein as potently as *P. notoginseng*. This was consistent with the findings that *P. notoginseng* and also berberine inhibited prostaglandin E2 synthesis induced by LPS.

Key words : iNOS, Cytokines, Cyclooxygenase-2(COX-2), lipopolysaccharide(LPS), Prostaglandin E2, berberine, *Panax notoginseng*

Introduction

NO has been shown to be an important regulatory molecule in diverse physiological functions such as vasodilation, neural communication, and host defense. Molecular cloning and sequencing analysis have revealed the existence of at least three main types of NOS isoforms³⁻⁵. NOS present in the vascular endothelium (eNOS) and that in central and peripheral neurons (nNOS) are constitutive (cNOS), and their activation is Ca²⁺-dependent. Continuous release of NO by cNOS plays a role in keeping the vasculature in an active state of vasodilation. Various agonists such as bradykinin and acetylcholine have been shown to trigger cNOS-mediated NO production through increasing intracellular Ca²⁺. NOS in macrophages and hepatocytes, on the other hand, is inducible (iNOS), and its activation is Ca²⁺-independent^{6,7}. After exposure to endotoxin and/or cytokines, iNOS can be induced in various cells such as macrophages, Kupffer cells, smooth

muscle cells, and hepatocytes. The induced iNOS catalyzes the formation and release of a large amount of NO, which plays a key role in the pathophysiology of a variety of diseases including septic shock⁸⁻¹¹. NO production catalyzed by iNOS, therefore, may reflect the degree of inflammation and provides a measure by which effects of drugs on the inflammatory process can be assessed. Expression of cyclooxygenase-2 (COX-2) in various tissue preparations following lipopolysaccharide (LPS) treatment also has been reported¹²⁻¹⁴. This enzyme is considered to play a major role in the inflammatory process by catalyzing the production of prostaglandins.

Herbal medicines that have been used in Korea for thousands of years are now being manufactured as drugs containing ingredients of standardized quality and quantity. The clinical efficacy of these medicines has been used by Korean Western-medicine practitioners for more than 20 years and is well recognized¹⁵. One of the herbal medicines, *Panax notoginseng*, is the most common drug to treat chronic liver disease in Korea. A Korean herbal medicine, *Panax notoginseng* (*P. notoginseng*, PNS) is highly prized in Korea for its therapeutic abilities to stop haemorrhages, to influence blood circulation and to act as a tonic agent. *P. notoginseng* is cultivated on a large scale in Korea. It is an oral medicine. The

* To whom correspondence should be addressed at : Won Hwan Park, Department of Diagnostics and Cardiovascular Medical Research Center, Dongguk University, Sukjang-Dong 707, Kyung-Ju 780-714, Korea.

· E-mail : diapwh@dongguk.ac.kr, · Tel : 054-770-2373

· Received : 2006/07/20 · Revised : 2006/09/01 · Accepted : 2006/09/29

main root of this plant, named notoginseng, is used for treatment of trauma and bleeding due to internal and external injury. *P. notoginseng* has many reported actions such as limitation of liver injury, anti-tumor effect, and alteration of the functional balance of the immune system¹⁶. Recently, *P. notoginseng* is widely used by patients with chronic hepatitis in Korean. The preparation prevented liver fibrosis as well as the development of HCC in patients with cirrhosis¹⁷. In addition, *P. notoginseng* was found to inhibit the activation of stellate cells, the rodent equivalent of human stellate cells. This is believed to be the mechanism of prevention of liver fibrosis by *P. notoginseng*¹⁷.

As the principal constituents of this medicinal herb, various dammarane-type triterpene saponins were isolated from the roots, leaves, and seeds¹⁸. Furthermore, its immunological adjuvant activities of the principal dammarane-type triterpene saponins from notoginseng and American ginseng were characterized¹⁹. Because of its major pharmaceutical effects, *P. notoginseng* is presumed to generally and gradually improve biological defense mechanisms, and it has been reported to have an anti-inflammatory action via an increase in blood corticosterone levels. However, its mode of action has not been fully elucidated. It was also found that the saponin fraction from the flower buds of *P. notoginseng* showed hepatoprotective effect on liver injury induced by D-galactosamine (D-GalN) and lipopolysaccharide (LPS) in mice. The flower buds of *P. notoginseng* have been used for treatment of hypertension, vertigo, tinnitus, and laryngopharyngitis, and several known dammarane-type triterpene saponins were hitherto isolated from the flower buds²⁰. New saponins from the flower buds of *P. notoginseng* as well as the hepatoprotective effects of the principal dammarane-type triterpene saponins have been characterized from the flower buds and roots²¹.

A number of traditional plant-derived medicines have been found to be rich in polyphenolic compounds²². These include flavonoids, tannins, and anthraquinones and have been shown to exhibit anti-inflammatory activities²³⁻²⁵. The exact mechanism of anti-inflammatory action of these compounds is not established. The possibility that these compounds exhibit their biological effects by blocking iNOS and COX-2 expression, therefore, was examined in the present study. Specifically, we studied the effect of *P. notoginseng* on LPS-induced NO and PGE₂ production and expression of iNOS and COX-2 in RAW264.7 macrophages. The data demonstrated that *P. notoginseng* was the most potent among the compounds tested in blocking LPS-induced iNOS and COX-2 gene expression. These inhibitory effects of *P. notoginseng* were also

demonstrated in Bcl-2-overexpressing RAW264.7 cells.

Materials and Methods

1. Cells

RAW264.7, a mouse macrophage cell line, was obtained from the American Type Culture Collection. Cells were cultured in RPMI-1640 medium supplemented with 2 mM glutamine, antibiotics (100 U/ml of penicillin A and 100 U/ml of streptomycin) and 10% heat-inactivated fetal bovine serum (Gibco/BRL) and maintained at 37°C in a humidified incubator containing 5% CO₂.

2. Plant Material

The flower buds of *Panax notoginseng* was purchased in Kyungju, Kyungbuk, Korea. A voucher of the plant is on file in our laboratory (2002. 09. PN-563). The dried flower buds of *P. notoginseng* (500 g) were finely cut and extracted three times by boiling water.

3. Water extraction of *P. notoginseng*

Authentic plant material was purchased from local market and identified at the Oriental Medical Department, Dongguk University, Kyungju, Korea. Voucher specimen [OM-S37] is present at the Herbarium of Botany Department, Dongguk University, Kyungju, Korea. More specifically, stems of *P. notoginseng* were cut into small pieces and 200 g of the material was boiled in 4 l of water until the liquid volume had been reduced by 50%. The fluid was then filtered through a 1 mm-pore-size filter, the water-insoluble component was discarded, and the *P. notoginseng* extract was lyophilized to a dry powder. Then, the *P. notoginseng* extract was filtered. The filtrate was evaporated to dryness in an oven at 40°C. The dried *P. notoginseng* extract was weighed (yield, 1.5%).

A sample of the dry powder (2.5 g) was dissolved in 100 ml of milli-Q water at 37°C and stirred for 60 min. The sample was then centrifuged at 4000 × g for 15 min, and the supernatant was passed through a 0.22 μm membrane bottle filter system (Corning, COstar, NY, USA). The water-insoluble component was discarded and the water-soluble ingredients were used in the experiments. The concentration of *P. notoginseng* extract in the solution was calculated by lyophilizing the water-soluble component that passed through a 0.22 μm membrane bottle filter. The concentration of LPS in *P. notoginseng* (600 g/ml) was 0.03 pg/ml.

4. Determination of Berberine from *P. notoginseng* stems

P. notoginseng stems (100 mg) were extracted with 2%

hydrochloric acid (10 mL) by ultrasonication for 30 min at 40°C, and cobalt thiocyanate reagent (2 mL) and dichloroethane (10 mL) were added. The mixture was shaken at 280 rev/min for 10 min and centrifuged at 2500 rev/min for 10 min. The aliquot (0.1 mL) of the organic layer was evaporated to dryness under the stream of nitrogen gas and the residue was dissolved in methanol (2 mL) to destroy the complex. Protoberberine-type alkaloids was extracted by Soxhlet extraction, ultrasonication or shaking with methanol or methanol-hydrochloric acid mixture (100:1). In this study, methanol was inappropriate as an extraction solvent because it hindered the complex formation of protoberberine-type alkaloids with cobalt thiocyanate. Ultrasonication of the samples with 2% hydrochloric acid for 30 min was enough for the extraction of berberine and palmatine from crude drugs. Protoberberine-type alkaloids formed green protoberberine-cobalt complexes, which were freely soluble in dichloromethane and dichloroethane compared to chloroform, ethyl acetate and benzene and had a specific absorbance at 625 nm. Therefore, dichloroethane was used as extraction solvent of protoberberine-cobalt complexes because of low volatility compared to dichloromethane. Addition of cobalt thiocyanate reagent and dichloroethane to 2% hydrochloric acid extracts of SB resulted in the selective extraction of protoberberine-type alkaloids as green protoberberine-cobalt complexes into the dichloroethane layer. The aliquot (5 µL) was injected onto HPLC. The HPLC system consisted of a SpectraSystem P4000 pump (Thermo Separation Products, CA), a Rheodyne 7125 injector (Cotati, CA), and a SpectraSystem UV3000 detector with a 6-l microbore cell. Data handling was performed by a PC1000 software program. The analytical column was a Capcell Pak UG 120 column (250×2 mm i.d., Shiseido, Tokyo, Japan) equipped with a Capcell Pak UG 120 guard column (10×2 mm i.d., Shiseido). The mobile phase was acetonitrile-phosphate buffer (50 mM, pH 4.5) containing sodium octanesulfonate (10 mM) (34:66) and the flow rate was 0.2 mL/min. Detection wavelength was 254 nm and column temperature was 30°C. For the recovery test, berberin were added to SB, in which their contents had already been determined by HPLC. Limit of quantitation (LOQ) was evaluated at a signal-to-noise ratio of 5:1.

Ion-pair HPLC methods²⁶⁾ and reversed-phase HPLC²⁷⁾ were reported for the simultaneous determination of protoberberine-type alkaloids. Sodium dodecyl sulfate was used as an ion-pair reagent at a concentration range of 17~50 mM at pH 2.2. In this study, a narrowbore HPLC method was chosen due to higher column efficiency, increased detectability and lower solvent consumption. Capcell Pak UG 120 column,

pH-stable octadecyl silica column, was used as the stationary phase. Effects of pH and the concentration of sodium octanesulfonate in mobile phase on capacity factor of berberine was evaluated to achieve satisfactory resolution; 34% acetonitrile in 0.05 µM phosphate buffer (pH 4.5) containing 10 mM sodium octanesulfonate was found to be the best. Isolated berberine from Korean herbal plant *P. notoginseng* is shown in Fig. 1. for the chemical structures shown in Fig. 1.

5. Nitrite assay

The nitrite concentration in the medium was measured as an indicator of NO production according to the Griess reaction²⁸⁾. One hundred microliters (100 µL) of each supernatant was mixed with the same volume of Griess reagent (1% sulfanilamide in 5% phosphoric acid and 0.1% naphthylethylenediamine dihydrochloride in water) absorbance of the mixture at 550 nm was determined with an ELISA plate reader (Dynatech MR-7000; Dynatech Laboratories).

6. Western blots

Total cellular extract, cytosolic fractions (for IB), and nuclear fraction (for p65) were prepared according to Muller et. al,²⁹⁾ separated on SDS-polyacrylamide minigels (8% for iNOS or COX-2, and 10% for IB or p65), and transferred to Immobilon polyvinylidene difluoride membranes (Millipore). The membrane was incubated overnight at 4°C with 1% bovine serum albumin and then incubated with anti-iNOS, anti-COX-2, or anti-tubulin monoclonal antibodies (Transduction Laboratories), or with anti-IB or anti-p65 polyclonal antibodies (Santa Cruz Biochemicals). iNOS, IB, p65, COX-2, and -tubulin were detected by NBT and BCIP staining (Sigma Chemical Co.).

7. Measurement of PGE2 production

RAW264.7 cells were subcultured in six-well plates and were incubated with Berberine for 12 hr. One hundred microliters (100 µL) of supernatant of culture medium was collected for the determination of PGE2 concentrations by ELISA (Cayman Enzyme Immunoassay kit).

Results

1. Effects of *P. notoginseng* and berberine on LPS-induced NO production in RAW264.7 macrophages

The chemical structure of the anthraquinone, berberine, that were used in the present study are shown in Fig. 1. The effects of the compound and *P. notoginseng* on NO production in RAW264.7 macrophages were investigated. The accumulated

nitrite, estimated by the Griess method, in the culture medium was used as an index for NO synthesis from these cells. *P. notoginseng*, at a concentration of 20 g/ml, did not interfere with the reaction between nitrite and Griess reagent (data not shown). Unstimulated macrophages, after 24 hr of incubation in culture, produced background levels of nitrite (Fig. 2). When the resting cells were incubated with each indicated compound alone, the concentration of nitrite in the medium was maintained at a background level similar to that in the unstimulated samples. After treatment with LPS (100 ng/ml) for 24 hr, nitrite concentration was increased markedly about 20-fold (35 M). When macrophages were incubated with various concentrations of *P. notoginseng* and berberine (5, 10, or 20 µg/ml) together with 100 ng/ml of LPS for 24 hr, significant concentration-dependent inhibition of nitrite production was found in the presence of *P. notoginseng* and berberine. Examination of the effects of *P. notoginseng* and berberine at 20 µg/ml on RAW264.7 cell viability as determined by the MTT assay indicated that only berberine at this high concentration caused slight cytotoxicity (30%), whereas *P. notoginseng* did not affect cell viability (data not shown).




Fig. 1. Chemical structures of berberine.




Fig. 2. Effects of *P. notoginseng* and berberine on LPS-induced nitrite production in RAW264.7 macrophages. The cells were treated with 100 ng/ml of LPS only or LPS plus 5 µg/ml (1), 10 µg/ml (2), or 20 µg/ml (3) of *P. notoginseng* and berberine at 37°C for 24 hr. At the end of each incubation, 100 µl of the medium was removed for measuring nitrite production. Control values were obtained in the absence of LPS or *P. notoginseng* and berberine. Data were obtained from three independent experiments and expressed as means ± SD. Key: (*) P < 0.05 and (**) P < 0.01 indicate significant differences from the LPS-treated group.

2. Effects of *P. notoginseng* and berberine on the expression of iNOS and COX-2 proteins in RAW264.7 macrophages

RAW264.7 macrophages did not express detectable iNOS protein when incubated in the medium alone for 24 or 7 hr, respectively. The basal level of iNOS in RAW264.7 cells was not affected when incubated with each of the eight compounds alone (data not shown), whereas 100 ng/ml of LPS induced a dramatic increase in iNOS protein in these cells. *P. notoginseng* and berberine inhibited LPS-induced iNOS protein in a concentration-dependent manner. The amount of α-tubulin protein as an internal control remained unchanged (Fig. 3).





Fig. 3. Inhibition of LPS-induced iNOS protein in RAW264.7 macrophages by *P. notoginseng* and berberine. The cells were treated as described in Fig. 2. A) *P. notoginseng* B) berberine. Equal amounts of total proteins (50 µg/lane) were subjected to 10% SDS-PAGE, and expression of iNOS and α-tubulin protein was detected by western blotting using specific anti-iNOS and anti-tubulin antibodies. α-Tubulin protein was used as an internal control. LPS = LPS-treated.

3. Effects of *P. notoginseng* and berberine on LPS-induced COX-2 protein expression

Since NO may directly activate expression of COX isoforms, and induction of COX gene expression has been shown to be involved in LPS-mediated response¹²⁻¹⁴, we investigated the effects of *P. notoginseng* and berberine on LPS-induced COX-2 protein expression. The results indicated that only *P. notoginseng* inhibited LPS-induced COX-2 expression at protein levels (Fig. 4. A,B). Furthermore, the marked increase in PGE₂, a product of the COX-2 enzyme, induced by LPS was inhibited significantly by *P. notoginseng* (1~20 µg/ml). On the other hand, berberine at similar concentrations inhibited LPS-induced PGE₂ production (Fig. 4C).






Fig. 4. Effects of *P. notoginseng* and berberine on production of COX-2 protein and PGE2 in RAW264.7 macrophages. Cells were treated with LPS (100 ng/ml) only, or LPS plus *P. notoginseng* (1-10 µg/ml) (A) or berberine (1-10 µg/ml) (B) for 24 hr. Detection of COX-2 protein was performed by western blotting using a specific anti-COX-2 antibody. α -Tubulin protein was used as an internal control among these eight compounds. (C) Effects of *P. notoginseng* and berberine on LPS-induced PGE2 synthesis in cultured smooth muscle cells. PGE2 concentrations in the culture medium were measured by ELISA. Key: (*, **) significantly different ($P < 0.05$ and $P < 0.01$) from LPS-treated samples.

Discussion and Conclusion

The extract from the flower buds of *P. notoginseng* cultivated in Kyungbuk province of Korea was partitioned into a water to furnish a soluble fraction. From natural plants, several polyphenolic compounds showed their biological activities such as anti-inflammatory³⁰⁾ and anti-carcinogenic activities³¹⁾. Medicinal plants have been used as traditional remedies for hundreds of years. Among these herbs, *P. notoginseng*, which has been traditionally used for hepatitis, inflammation, osteomyelitis and gynecological diseases in Korea and China, was found to show potent anti-inflammatory effect. The water extract from the stems of *P. notoginseng* was found to inhibit inflammation. *P. notoginseng* has been used in Chinese and Korean medicine as a remedy for treating inflammation, suppurative dermatitis, allergic diseases and gynecological diseases. By bioassay-guided separation, emodin, emodin 8-O-glucopyranoside, resveratrol, baicalin, and berberine were isolated as active principles. The plant has been reported to contain a large number of flavonoids, frequently found as glucosides and other constituents, including phenethyl alcohols, sterols, and essential oils and amino acids, although the active principles in SB have not been determined fully.

Results of the present study indicated that *P. notoginseng* and berberine differentially inhibited LPS-induced NO production and iNOS expression in RAW264.7 macrophages. *P. notoginseng* and berberine were potent inhibitors of LPS-induced NO production and iNOS expression. The mechanisms of inhibition of iNOS by *P. notoginseng* and berberine, however, were different. The finding is consistent with reports by others that the immunosuppressive effect of

berberine in human mononuclear cells is not affected by indomethacin (a nonspecific COX-2 inhibitor)³²⁾.

P. notoginseng has been used in Chinese medicine as a remedy for treating inflammation, suppurative dermatitis, allergic diseases, hyperlipemia, and arteriosclerosis³³⁾. The active principle in *P. notoginseng* that exhibits these beneficial effects, however, has not been determined fully. Results of the present study indicated that *P. notoginseng* inhibited the LPS induction of iNOS and COX-2 expression in macrophages without appreciable cytotoxic effects. These findings were consistent with a decrease caused by *P. notoginseng* in LPS-induced NO and PGE2 production. These results suggest that *P. notoginseng* may play an important role in inhibiting inflammatory processes.

Berberine, flavonoid derivative isolated from *P. notoginseng*, which also has been used in Chinese medicine to treat various diseases including inflammation, is another potent inhibitor of LPS-induced NO production and iNOS protein synthesis. At 20 µg/ml, it almost abolished LPS-induced iNOS protein synthesis and NO production. Berberine was the compound exhibiting no cytotoxicity of the cells at 24 hr post-treatment (not shown). This result suggests that the decrease in iNOS proteins and NO production 24 hr after treatment with berberine may be due to its direct effect on NO production. It has been established that RAW264.7 macrophages are highly susceptible to endogenously generated or exogenously supplied NO³⁴⁾. Treatment of RAW264.7 macrophages with LPS and IFN has been shown to result in NOS induction and apoptosis. Both nitrite accumulation and apoptosis were blocked by the NOS inhibitor NG-monomethyl-arginine.

In summary, results of the present study indicated that *P. notoginseng* was an effective inhibitor of LPS-induced iNOS and COX-2 expression in RAW264.7 macrophages. Berberine, which also inhibited LPS-induced nitrite production and iNOS protein. *P. notoginseng* appears to be a potential therapeutic agent for treating LPS-induced sepsis syndrome.

Acknowledgements

This work was supported by the research program of Dongguk University and the MRC program of MOST/KOSEF (grant # : R13-2005-013-01000-0), Korea

References

1. S. Moncada, R.M.J. Palmer and D.A. Higgs. Nitric oxide: Physiology, pathophysiology, and pharmacology.

- Pharmacol Rev 43:109-142, 1992.
2. M.A. Marletta, P.S. Yoon, R. Iyengar, C.D. Leaf and J.S. Wishnok. Macrophage oxidation of L-arginine to nitrite and nitrate: Nitric oxide is an intermediate. *Biochemistry* 27:8706-8711, 1988.
 3. C. Nathan. Nitric oxide as a secretory product of mammalian cells. *FASEB J* 6:3051-3064, 1992.
 4. M.A. Marletta. Mammalian synthesis of nitrite, nitrate, nitric oxide and N-nitrosating agents. *Chem Res Toxicol* 1:249-257, 1988.
 5. M.A. Marletta. Nitric oxide synthase structure and mechanism. *J Biol Chem* 268:12231-12233, 1993.
 6. D.L. Duval, D.R. Miller, J. Collier and R.E. Billings. Characterization of hepatic nitric oxide synthase: Identification as the cytokine-inducible form primarily regulated by oxidants. *Mol Pharmacol* 50:277-284, 1996.
 7. T. Yuan, H.T. Vogel, C. Sutherland and M.P. Walsh. Characterization of the Ca²⁺-dependent and -independent interactions between calmodulin and its binding domain of inducible nitric oxide synthase. *FEBS Lett* 431:210-214, 1998.
 8. R.H. Liu and J.H. Hotchkiss. Potential genotoxicity of chronically elevated nitric oxide: A review. *Mutat Res* 339:73-89, 1995.
 9. A. Pedoto, A.K. Tassiopoulos, A. Oler, D.J. McGraw, S.P. Hoffmann, E.M. Camporesi and T.S. Hakim. Treatment of septic shock in rats with nitric oxide synthase inhibitors and inhaled nitric oxide. *Crit Care Med* 26:2021-2028, 1998.
 10. B. Tunctan, O. Uludag, S. Altug and N. Abacioglu. Effects of nitric oxide synthase inhibition in lipopolysaccharide-induced sepsis in mice. *Pharmacol Res* 38:405-411, 1998.
 11. M. Ueno and T.J.-F. Lee. Endotoxin decreases the contractile responses of the porcine basilar artery to vasoactive substances. *J Cereb Blood Flow Metab* 13:712-719, 1993.
 12. C. Cao, K. Matsumura, K. Yamagata and Y. Watanabe. Induction by lipopolysaccharide of cyclooxygenase-2 mRNA in rat brain; its possible role in the febrile response. *Brain Res* 697:187-196, 1995.
 13. N. Quan, M. Whiteside and M. Herkenham. Cyclooxygenase 2 mRNA expression in rat brain after peripheral injection of lipopolysaccharide. *Brain Res* 802:189-197, 1998.
 14. S.H. Lee, E. Soyoola, P. Chanmugam, S. Hart, W. Sun, H. Zhong, S. Liou, D. Simmons and D. Hwang. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. *J Biol Chem* 267:2593-25938, 1992.
 15. Fujiwara, K., Ohta, Y., Ogata, I. Treatment trial of traditional oriental medicine in chronic viral hepatitis. In: Ohta Y, ed. *New Trends in Peptic Ulcer and Chronic Hepatitis: Part II Chronic Hepatitis*. Tokyo: Excerpta Medica, 141-146, 1987
 16. Li, X.C. Chinese herbal study on anti-ischemia-reperfusion-injury. *Chinese Journal of Hospital Pharmacy* 154:1-4, 1998.
 17. Zhang, G.Q., Ye, R.G., Kong, Q.Y., Yang, N.S., Zhang, J.L., Guan, W.M. and Chen, Y.X. Panax notoginseng saponins induced of human renal interstitial fibroblasts and its mechanisms. *Chinese Journal of Nephrology* 14(2):93-95, 1998.
 18. Sanada, S., Shoji, J., *Shoyakugaku Zasshi*, 32:96-99, 1978.
 19. Yoshikawa, M., Morikawa, T., Yashiro, K., Murakami, T., Matsuda, H. *Chem. Pharm. Bull.* 49:1452-1456, 2001.
 20. Taniyasu, S., Tanaka, O., Yang, T.-R., Zhou, J. *Planta Med.* 44:124-12, 1982.
 21. (a) Wu, M.Z. *Yunnan Chih Wu Ten Chiu* 1:119-124, 1979. (b) Wei, C.H., Wang, C.F., Chang, L.Y., Tu, Y.C. *Yao Hsueh Tung Dao* 15:43-44, 1980. (c) Zhou, J., Wu, M.Z., Taniyasu, S., Besso, H., Tanaka, O., Saruwatari, Y., Fuwa, T. *Chem. Pharm. Bull.* 29:2844-2850, 1981. (d) Yang, T.R., Kasai, R., Zhou, J., Tanaka, O. *Phytochemistry* 22:1473-1478, 1983. (e) Matsuura, H., Kasai, R., Tanaka, O., Saruwatari, Y., Fuwa, T., Zhou, J. *Chem. Pharm. Bull.* 31:2281-2287, 1983. (f) Namba, T., Matsushige, K., Morita, T., Tanaka, O. *Chem. Pharm. Bull.* 34:736-738, 1986. (g) Yamaguchi, H., Kasai, R., Matsuura, H., Tanaka, O., Fuwa, T. *Chem. Pharm. Bull.* 36:3468-347, 1988.
 22. E. Haslam, T.H., Lelly, C., Ya, R., Martin and D. Magnolato. Traditional herbal medicine. The role of plant polyphenols. *Planta Med* 55:1-8, 1989.
 23. K. Aoki, H. Maruta, F. Uchiumi, T. Hatano, T. Yoshida and S. Tanuma. A macrocyclic ellagitannin, oenothien B, suppresses mouse mammary tumor gene expression via inhibition of poly(ADP-ribose) glycohydrolase. *Biochem Biophys Res Commun* 210:329-337, 1995.
 24. K. Yasukawa, M. Takido, M. Takeuchi, Y. Sato, K. Nitta and S. Nakagawa. Inhibitory effects of flavonol glycosides on 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion. *Chem Biol Bull* 38:774-776, 1990.
 25. K. Miyamoto, M. Nomura, M. Sasakura, E. Matsui, R. Koshiura, T. Murayama, T. Furukawa, T. Hatano, T. Yoshida and T. Okuda. Anti-tumor activity of oenothien B, a unique macrocyclic ellagitannin. *Jpn J Cancer Res* 84:99-103, 1993.
 26. T. Misaki, K. Sagara, M. Ojima, S. Kakizawa, T. Oshima and H. Yoshizawa. Simultaneous determination of berberine, palmatine and coptisine in crude drugs and

- oriental pharmaceutical preparations by ion-pair high-performance liquid chromatography. *Chem. Pharm. Bull.* 30:354-357, 1982.
27. H.S. Lee, Y.E. Eom and D.O. Eom. Narrowbore high performance liquid chromatography of berberine and palmatine in crude drugs and pharmaceuticals with ion-pair extraction using cobalt thiocyanate reagent. *Pharm Biomed Anal.* 21:59-63, 1999.
 28. H. Kim, H.S. Lee, K.T. Chang, T.H. Ko, K.J. Baek and N.S. Kwon. Chloromethyl ketones block induction of nitric oxide synthase in murine macrophages by preventing activation of nuclear factor- κ B. *J Immunol* 154:4741-4748, 1995.
 29. J.M. Muller, H.W. Loms Ziegler-Heitbrock and P.A. Baeuerle. Nuclear factor kappa B, a mediator of lipopolysaccharide effects. *Immunobiology* 187:233-256, 1993.
 30. F. Yang, W.J. de Villiers, C.J. McClain and G.W. Varilek. Green tea polyphenols block endotoxin-induced tumor necrosis factor-production and lethality in a murine model. *J. Nutr.* 128:2334-2340, 1998.
 31. J.K. Lin, Y.C. Liang and S.Y. Lin-Shiau. Cancer chemoprevention by tea polyphenols through mitotic signal transduction blockade. *Biochem. Pharmacol.* 58:911-915, 1998.
 32. H.C. Huang, J.H. Chang, S.F. Tung, R.T. Wu, M.L. Foegh and S.H. Chu. Immunosuppressive effect of Berberine, a free radical generator. *Eur J Pharmacol* 211:359-364, 1992.
 33. Ma, L.Y. and Xiao, P.G. Effects of saponins of *Panax notoginseng* on intracellular free Ca^{2+} concentration in dissociated neurons. *Chinese Pharmaceutical Journal* 33(8):467-469, 1998.
 34. U.K. Meßmer, E.G. Lapetina and B. Brune. Nitric oxide-induced apoptosis in RAW 264.7 macrophages is antagonized by protein kinase C- and protein kinase A-activating compounds. *Mol Pharmacol* 47:757-765, 1995.